natgillin/translations-raw huggingface dataset:
tiredness, diarrhoea, nausea, vomiting and abdominal pain.
umor, proljev, mučninu, povraćanje i bol u trbuhu.
Tiredness, difficulties in walking, unusual tiredness and weakness (asthenia), feeling drunk
umor, poteškoće hoda, neuobičajeni umor i slabost (astenija), osjećaj opijenosti
tiredness, exhaustion
umor, iscrpljenost
Tiredness, fatigue, pale skin (signs of low level of red blood cells)
Zamor, umor, blijeda koža (znakovi niske razine crvenih krvnih stanica)
Tiredness, feeling sleepy (somnolence)
umor, osjećaj pospanosti (somnolencija)
tiredness, feeling weak
umor, osjećaj slabosti
tiredness, feeling weak fever.
umor, osjećaj slabosti vrućica.
Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting (thrombosis/thromboembolism).
umor, gljivične infekcije, smetenost, halucinacije, povraćanje, poremećaj hoda, zatajenje srca i zgrušavanje venske krvi (tromboza/tromboembolija).
tiredness, general weakness
umor, opća slabost
Tiredness, increased thirst and/or a need to pass urine more frequently than usual, as these may be signs of an increase in the amount of sugar in your blood
Umor, povećana žeđ i/ili češća potreba za mokrenjem nego što je uobičajeno, jer bi to mogli biti znakovi povećane količine šećera u krvi.
Tiredness, itchy skin, yellowing of your skin or the whites of your eyes, nausea (feeling sick) or vomiting, decreased appetite, pain on the right side of your abdomen (belly), dark or brown urine, bleeding or bruising more easily than normal (potential signs or symptoms of liver problems)
Umor, svrbež kože, žutilo kože ili bjeloočnica, mučnina ili povraćanje, smanjeni apetit, bol na desnoj strani abdomena (trbuha), tamna ili smeđa mokraća, krvarenje ili stvaranje modrica lakše nego što je normalno (potencijalni znakovi ili simptomi problema s jetrom)
Tiredness, joint pain and increased sweating.
Umor, bol u zglobovima i povećano znojenje.
tiredness, lack of energy
umor, gubitak energije
tiredness, lack of energy
umor, nedostatak energije
tiredness, lack of energy or general weakness
umor, nedostatak energije ili opća slabost
tiredness, muscle pain
umor, mišićna bol
tiredness, pain, redness, swelling, hardness or itching at the injection site.
umor, bol, crvenilo, oticanje, otvrdnuće ili svrbež na mjestu injiciranja.
tiredness, unusual tiredness or weakness; fever increased liver blood tests; abnormal white blood cells; increased fat levels in blood; increased level of enzyme from salivary glands or pancreas
umor, neuobičajen umor ili slabost; vrućica povišene vrijednosti testova jetrene funkcije; promjene na bijelim krvnim stanicama; povišene razine masnoća u krvi; povišene vrijednosti enzima iz žlijezda slinovnica ili gušterače.
Tiredness, weakness and lower tolerance to exercise
umor, slabost i slabije podnošenje fizičkog napora
Tiredness, weakness, influenza-like illness.
Umor, slabost, bolest nalik gripi.
Tiredness, weakness, swelling of the body and face.
Umor, slabost, oticanje tijela i lica.
Tiredness.
umor.
tiredness; or flu-like symptoms weight gain or loss
umor; ili simptomi nalik gripi dobitak ili gubitak na težini.
tiredness; or flu-like symptoms weight gain or loss.
umor ili simptomi nalik gripi dobitak ili gubitak na težini.
tiredness; or flu-like symptoms weight gain or loss.
umor; ili simptomi nalik gripi dobitak ili gubitak na težini.
tirofiban, defibrotide.
tirofiban, defibrotid.
Tissue culture infectious dose 50%
50 % infektivne doze kulture tkiva
tissue disorders
i potkožnog tkiva
tissue disorders
istemskim
tissue disorders
koštanog
TISSUE DISORDERS
POREMEĆAJI
tissue disorders
Poremećaji bubrega i mokraćnog sustava
tissue disorders
Poremećaji kože i potkožnog tkiva
TISSUE DISORDERS
POTKOŽNOG TKIVA
TISSUE DISORDERS
SUSTAVA I VEZIVNOG
tissue disorders
ustava i vezivnog
Tissue distribution of drugs which are transported by P-gp may be increased.
Distribucija u tkivima lijekova koji se prenose P- gp-om može biti povećana.
Tissue outside the target area must be shielded completely to avoid photoactivation by scattered or reflected light.
Tkivo izvan ciljnog područja mora se potpuno zaštititi, kako bi se izbjegla fotoaktivacija raspršenom ili reflektiranom svjetlošću.
tissue swelling
otok tkiva
Tissue swelling (peripheral oedema)
Oticanje tkiva (periferni edem)
tissue swelling caused by excess fluid
oticanje tkiva uzrokovano prekomjernim nakupljanjem tekućine
tissue swelling in face caused by excess fluid
oticanje tkiva lica uzrokovano prekomjernim nakupljanjem tekućine
Tissue type used for assay, date of tissue biopsy, assay type and definition used for RET mutation positive and negative will be collected.
Prikupljat će se podaci o vrsti tkiva korištenog u testu, datumu biopsije tkiva, vrsti testa i definiciji prema kojoj je uzorak određen kao pozitivan odnosno negativan na RET mutaciju.
tissues and organs within the belly (intra-abdominal infections);
tkiva i organe unutar trbuha (intraabdominalne infekcije);
tissues disorders
potkožnog tkiva
Titanium Dioxide
titanijev dioksid
Titanium dioxide (E 171) Sodium laurilsulfate Water
Titanijev dioksid (E171) Natrijev laurilsulfat Voda
Titanium dioxide (E 171), Talc,
hipromeloza, titanijev dioksid (E171), talk,
Titanium dioxide (E-171) Polyethylene glycol 400
hipromeloza titanijev dioksid (E 171) polietilenglikol 400
Titanium dioxide (E171)
propilenglikol titanijev dioksid (E171)
Titanium dioxide (E171)
Titanov dioksid (E171)
Titanium dioxide (E171)
šelak titanijev dioksid (E171)
Titanium dioxide (E171) Aspartame (E951)
Eritrozin (E127) Titanijev dioksid (E171) Aspartam (E951)
Titanium dioxide (E171) Brilliant Blue FCF (E133) Yellow iron oxide (E172)
želatina titanijev dioksid (E171) brilliant blue FCF (E133) željezov oksid, žuti (E172)
Titanium dioxide (E171) Erythrosine (E127) Indigotine (E132)
Titanijev dioksid (E171) Eritrozin (E127) Indigotin (E132)
Titanium dioxide (E171) Gelatin
titanijev dioksid (E171) želatina
Titanium dioxide (E171) Indigo carmine (E132).
voda titanijev dioksid (E171) indigo karmin (E132)
Titanium dioxide (E171) Iron oxide red (E172)
voda titanijev dioksid (E171) željezov oksid, žuti (E172)
Titanium dioxide (E171) Iron oxide red (E172) Magnesium stearate
Titanijev dioksid (E171) Željezov oksid crveni (E172) Magnezijev stearat
Titanium dioxide (E171) Iron oxide red (E172) Sodium laurilsulfate
želatina titanijev dioksid (E171) željezov oksid, crveni (E172) natrijev laurilsulfat
Titanium dioxide (E171) Iron oxide yellow (E172)
voda titanijev dioksid (E171) željezov oksid, žuti (E172)
Titanium dioxide (E171) Iron oxide yellow (E172) Indigo carmine (E132)
voda titanijev dioksid (E171) željezov oksid, žuti (E172) indigo karmin (E132).
Titanium dioxide (E171) Iron oxide yellow (E172) Iron oxide red (E172)
voda titanijev dioksid (E171) željezov oksid, žuti (E172) željezov oksid, crveni (E172)
Titanium dioxide (E171) Macrogol 400 (E1521)
Titanijev dioksid (E171) Makrogol 400 (E1521)
Titanium dioxide (E171) Polyethylene glycol 400 Ferric oxide (red) (E172) Carnauba wax
hipromeloza titanijev dioksid (E171) polietilenglikol 400 željezov oksid (crveni) (E172) karnauba vosak
Titanium dioxide (E171) Polyethylene glycol 400 Ferric oxide (yellow) (E172) Carnauba wax
hipromeloza titanijev dioksid (E171) polietilenglikol 400 željezov oksid (žuti) (E172) karnauba vosak
Titanium dioxide (E171) Polyethylene glycol 400 Ferric oxide (yellow) (E172) Ferric oxide (red) (E172) Carnauba wax
hipromeloza titanijev dioksid (E171) polietilenglikol 400 željezov oksid (žuti) (E172) željezov oksid (crveni) (E172) karnauba vosak
Titanium dioxide (E171) Printing ink
voda titanijev dioksid (E171) Tinta za označavanje
Titanium dioxide (E171) red iron oxide (E172)
Titanijev dioksid (E171) Željezov oksid, crveni (E172)
Titanium dioxide (E171) Sodium laurilsulfate
želatina titanijev dioksid (E171) natrijev laurilsulfat
Titanium dioxide (E171) Talc
Titanijev dioksid (E171) Talk
Titanium dioxide (E171) Triacetin (E1518)
Titanijev dioksid (E171) Triacetin (E1518)
Titanium dioxide (E171) Triethyl citrate
Ovojnica kapsule:
Titanium dioxide (E171) Yellow iron oxide (E172)
titanijev dioksid (E171) željezov oksid, žuti (E172)
Titanium dioxide (E171) Yellow iron oxide (E172)
želatina titanijev dioksid (E171) željezov oksid, žuti (E172)
Titanium dioxide (E171) Yellow iron oxide (E172) Red iron oxide (E172) Black iron oxide (E172)
želatina titanijev dioksid (E171) željezov oksid, žuti (E172) željezov oksid, crveni (E172) željezov oksid, crni (E172)
titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), black iron oxide (E172), sodium lauryl sulphate,
Ovojnica kapsule želatina, titanijev dioksid (E171), željezov oksid, crveni (E172), željezov oksid, žuti (E172), željezov oksid, crni (E172), natrijev laurilsulfat,
titanium dioxide macrogol 400
titanijev dioksid makrogol 400 polisorbat 80
titrated to obtain the desired clinical
kako bi se postigao željeni klinički
Titration diary 18
Dnevnik titracije 18
TITRATION GUIDE - TITRATION PACK
VODIČ ZA TITRACIJU - PAKIRANJE ZA TITRACIJU DOZE
Titration guide tool
Vodič za titraciju
Titration in patients not switching from other fentanyl containing products
Titracija u bolesnika koji se ne prebacuju s drugih lijekova koji sadrže fentanil
Titration in patients switching between immediate-release fentanyl containing products
Titracija u bolesnika koji prelaze s jednog lijeka s trenutačnim otpuštanjem fentanila na drugi takav lijek
Titration in patients switching from other fentanyl containing products
Titracija u bolesnika koji su primali druge lijekove koji sadrže fentanil
titration of the antidepressant based on a clinical assessment of antidepressant response.
procjeni odgovora na antidepresiv.
Titration of the dose of this medicinal product is not required.
Nije potrebno titrirati dozu ovog lijeka.
Titration of the insulin glargine dose was managed by the patient after instruction by the investigator:
Titriranje doze glargin inzulina regulirao je bolesnik prema uputama dobivenima od ispitivača:
Titration pack
Titracijsko pakiranje
Titration pack for dose titration with 4 differently coloured and numbered triple packs:
Titracijsko pakiranje za titraciju doze s 4 različito obojana i numerirana trostruka pakiranja:
Titration Step
Titracijski korak
Titration to a higher dose necessitates contact with the health care professional.
Titracija do veće doze zahtijeva nadzor zdravstvenog djelatnika.
Titration using the BIOSET or pre-filled syringe can be achieved by initiating therapy on ¼ dose increments per week reaching the full dose (30 micrograms/week) by the fourth week.
Koristeći BIOSET ili napunjenu štrcaljku titriranje se može provesti započinjanjem terapije ¼ doze te tolikim povišenjem doze svaki tjedan postižući tako punu dozu (30 mikrograma/tjedan) u četvrtom tjednu.
Titration was performed as outlined in Table 2 though with a titration target of 4-6 mmol/L.
Titracija je provedena onako kako je navedeno u Tablici 2, ali je cilj titracije bila vrijednost od 4-6 mmol/l.
Titration: To help patients reduce the incidence and severity of flu-like symptoms (see section 4.8), titration can be performed at the initiation of treatment.
Titracija: Na početku liječenja može se provesti titracija kako bi kod bolesnika smanjila incidencija i težina simptoma sličnih gripi (vidjeti dio 4.8).
tituted
rekonstituiranog
Tivicay 50 mg film-coated tablets dolutegravir
Tivicay 50 mg filmom obložene tablete dolutegravir
Tivicay 50 mg tablets dolutegravir
Tivicay 50 mg tablete dolutegravir
Tivicay can only be obtained with a prescription and should be prescribed by a doctor who is experienced in managing HIV infection.
Tivicay se izdaje samo na liječnički recept te ga smije propisati liječnik s iskustvom u upravljanju infekcijom HIV-a.
Tivicay does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Tivicay ne liječi infekciju HIV-a ili SIDA-e, no može odgoditi oštećenje imunosnog sustava i razvoj infekcija i bolesti povezane sa SIDA-om.
Tivicay film-coated tablets are yellow, round, biconvex tablets marked with the code ‘SV 572’ on one side and ‘50’ on the other side.
Tivicay filmom obložene tablete su okrugle, bikonveksne tablete žute boje s oznakom ‘SV 572’ s jedne strane i ‘50’ s druge strane.
Tivicay is an antiviral medicine containing the active substance dolutegravir.
Tivicay je antivirusni lijek koji sadrži djelatnu tvar dolutegravir.
Tivicay is available as tablets (50 mg).
Tivicay je dostupan kao tablete (50 mg).
Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age.
Tivicay je indiciran u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje odraslih bolesnika i adolescenata starijih od 12 godina inficiranih virusom humane imunodeficijencije (HIV) .
Tivicay is used to treat HIV (human immunodeficiency virus) infection in adults and adolescents over 12 years old.
Tivicay se koristi za liječenje infekcije HIV-om (virusom humane imunodeficijencije) u odraslih osoba i adolescenata starijih od 12 godina.
Tivicay should be administered twice daily in this population when co-administered with some medicines (e.g. efavirenz, nevirapine, tipranavir/ritonavir, or rifampicin).
Tivicay se u toj populaciji mora primjenjivati dvaput na dan ako se uzima istodobno s nekim lijekovima (npr. efavirenzom, nevirapinom, tipranavirom/ritonavirom ili rifampicinom).
Tivicay should be prescribed by physicians experienced in the management of HIV infection.
Tivicay moraju propisati liječnici s iskustvom u liječenju HIV infekcije.
Tivicay should not be used in children and adolescents with HIV infection that is resistant to other medicines similar to Tivicay.
Tivicay se ne smije davati djeci i adolescentima s HIV infekcijom otpornom na druge lijekove slične lijeku Tivicay.
Tivicay was demonstrated to be effective against HIV-1 in four main studies.
Tivicay se pokazao djelotvornim protiv virusa HIV-1 u četiri glavna ispitivanja.
tizanidine (used as a muscle relaxant), cholestyramine (used to lower cholesterol levels in the blood).
tizanidin (koristi se kao lijek za opuštanje mišića), kolestiramin (koristi se za snižavanje razina kolesterola u krvi).
tizanidine, a muscle relaxant
tizanidin, lijek za opuštanje mišića
tlag (hrs)
tlag (sati)
Tlf : +46 8 545 80 230
Tlf :+46 8 545 80 230
Tlf. +47 23177200 healthcare@no.aga.com
GR-19600 Μάνδρα Αττικής Τηλ: 0030 211-1045500-510 healthcare@gr.linde-gas.com
Tlf: + 46 (0) 8 501 01 600 (Sverige)
Tel: + 31 (0) 900 575 3340
Tlf: + 46 (0) 8 501 01 600 (Sverige)
Tel: + 31 (0) 900 575 3340 (België/Belgique)
Tlf: + 46 (0) 8 501 01 600 (Sverige)
Tlf: + 46 (0) 8 501 01 600' (Sverige)
Tlf: + 46 (0)8 643 67 66 (SE)
Tel.: + 361 (0) 355 8490
Tlf: + 46 (0)8 643 67 66 (SE) Tel: + 46 8 643 67 66
Tel: + 46 8 643 67 66
Tlf: + 46 855 522 750 (Sverige)
Tlf: +46 855 522 750 (Sverige)
Tlf: +45 - 36 39 99 99
Tlf: +45 - 36 39 99 99 (See United Kingdom)
Tlf: +45 44 20 11 00
Tel.: +36-1-488-37-00
Tlf: +45 44 20 11 00
Tlf: +45 44 20 11 00 Tel :+356 21220174
Tlf: +45 72 30-20-28
Tlf: + 45 72 30-20-28
Tlf: +47 23130500
Tlf: +47 24 11 18 00
Tlf: +47 67 52 61 00
Tel: +31 (0)10 406 43 01
Tlf: +47 67 81 80 00
Tel: +353 (0)1 4287900
Tlf: +47 67 81 80 00
Tlf: + 47 67 81 80 00
Tlf: +47-23 13 05 00
Tlf: +47 23 13 05 00
TMA event-free status
Stanje bez TMA incidenta
TMA Event-Free Status, n (%)
Status bez TMA događaja, n (%)
TMA Event-free Status, n (%) 95% CI
Status bez događaja TMA, n (%)
TMA, including thrombotic thrombocytopaenic purpura (TTP) and haemolytic uremic syndrome (HUS), sometimes leading to renal failure or a fatal outcome, has been reported in clinical trials and in post-marketing experience of sunitinib as monotherapy and in combination with bevacizumab.
TMA, uključujući trombotičku trombocitopeničnu purpuru (TTP) i hemolitički uremički sindrom (HUS), koji katkada uzrokuje zatajenje bubrega ili fatalni ishod, prijavljen je u kliničkim ispitivanjima i u razdoblju nakon stavljanja u promet, kada se sunitinib primijenjivao kao monoterapija i u kombinaciji s bevacizumabom.
Tmax (h)
Tmax (sati)
Tmax (hr) mean(S.D.), range
Tmax (hr) srednja vrijednost (S.D.), raspon
tmax (hrs)
tmax (sati)
Tmax (minute) **
Tmax (minuta)
Tmax is between 3 and8 hours.
Vrijednost Tmax je između 3 i 8 sati.
Tmax was similar with both formulations.
Tmax je bio sličan u oba farmaceutska oblika .
Tmax, minute¶
Tmax, minuta¶
TMC125-C227 was an exploratory, randomised, active-controlled open-label trial, which investigated the efficacy and safety of INTELENCE in a treatment regimen, which is not approved under the current indication.
Ispitivanje TMC125-C227 bilo je eksplorativno, randomizirano, otvoreno ispitivanje s aktivnom kontrolom kojim se ispitivala djelotvornost i sigurnost primjene INTELENCEa u liječenju izvan odobrenih indikacija.
TMZ + concomitant RT n = 288*
TMZ + istodobna RT n = 288
TMZ + concomitant RT n=288*
TMZ + istodobna RT n = 288
TMZ + concomitant RT n=288*
Vaginalno krvarenje, menoragija, amenoreja, vaginitis, bol u dojkama
TMZ administration can be continued throughout the 42 day concomitant period (up to 49 days) if all of the following conditions are met: absolute neutrophil count (ANC) ≥ 1.5 x 109/l
Davanje TMZ-a može se nastaviti tijekom 42 dana faze istodobnog liječenja (do najviše 49 dana) ako su zadovoljeni svi sljedeći uvjeti: apsolutni broj neutrofila (ABN) ≥ 1,5 x 109/l
TMZ administration can be continued throughout the 42 day concomitant period (up to 49 days) if all of the following conditions are met: absolute neutrophil count (ANC) ≥ 1.5 x 109/l
Davanje TMZ-a može se nastaviti tijekom 42 dana faze istodobnog liječenja (do najviše 49 dana) ako su zadovoljeni svi sljedeći uvjeti: apsolutni broj neutrofila (ABN) ≥ 1,5 x 109/l broj trombocita ≥ 100 x 109/l
TMZ administration can be continued throughout the 42 day concomitant period (up to 49 days) if all of the following conditions are met: absolute neutrophil count (ANC) ≥ 1.5 x 109/l thrombocyte count ≥ 100 x 109/l
Davanje TMZ-a može se nastaviti tijekom 42 dana faze istodobnog liječenja (do najviše 49 dana) ako su zadovoljeni svi sljedeći uvjeti: apsolutni broj neutrofila (ABN) ≥ 1,5 x 109/l
TMZ administration can be continued throughout the 42 day concomitant period (up to 49 days) if all of the following conditions are met: absolute neutrophil count (ANC) ≥ 1.5 x 109/l thrombocyte count ≥ 100 x 109/l
Davanje TMZ-a može se nastaviti tijekom 42 dana faze istodobnog liječenja (do najviše 49 dana) ako su zadovoljeni svi sljedeći uvjeti: apsolutni broj neutrofila (ABN) ≥ 1,5 x 109/l broj trombocita ≥ 100 x 109/l
TMZ demonstrates low protein binding (10 % to 20 %), and thus it is not expected to interact with highly protein-bound substances.
TMZ se slabo veže za proteine (10 do 20 %), pa se stoga ne očekuje da ulazi u interakcije s tvarima koje imaju visok afinitet vezanja za proteine.
TMZ demonstrates low protein binding (10 % to 20 %), and thus it is not expected to interact with highly protein-bound substances.
TMZ se slabo veže za proteine (10 do 20%), pa se stoga ne očekuje da ulazi u interakcije s tvarima koje imaju visok afinitet vezanja za proteine.
TMZ dose (mg/m2
Doza TMZ-a (mg/m2/dan)
TMZ dose (mg/m²/day)
Doza TMZ-a (mg/m2/dan)
TMZ dose reduction or discontinuation during monotherapy treatment
Smanjenje doze ili prekid primjene TMZ-a u fazi monoterapije
TMZ dose(mg/m2
Doza TMZ-a (mg/m2/dan)
TMZ dosing interruption or discontinuation duringconcomitant radiotherapy and TMZ
Privremen ili trajan prekid primjene TMZ-a tijekom faze istodobnog liječenja radioterapijom i TMZ-om
TMZ has minor influence on the ability to drive and use machines due to fatigue and somnolence (see section 4.8) .
TMZ malo utječe na sposobnost upravljanja vozilima i rada sa strojevima zbog umora i somnolencije (vidjeti dio 4.8).
TMZ has minor influence on the ability to drive and use machines due to fatigue and somnolence (see section 4.8).
TMZ malo utječe na sposobnost upravljanja vozilima i rada na strojevima zbog umora i somnolencije (vidjeti dio 4.8).
TMZ has minor influence on the ability to drive and use machines due to fatigue and somnolence (see sections 4.8).
TMZ malo utječe na sposobnost upravljanja vozilima i rada sa strojevima zbog umora i somnolencije (vidjeti dio 4.8).
TMZ has minor influences on the ability to drive and use machines due to fatigue and somnolence (see section 4.8).
TMZ malo utječe na sposobnost upravljanja vozilima i rada sa strojevima zbog umora i somnolencije (vidjeti dio 4.8).
TMZ interruptiona
Privremeni prekid primjene TMZ-aa
TMZ interruptiona
Privremeni rekid primjene TMZ-aa
TMZ is administered at a dose of 75 mg/m2 daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions).
TMZ se primjenjuje peroralno u dozi od 75 mg/m2 na dan tijekom 42 dana uz istodobnu radioterapiju (60 Gy primijenjenih u 30 frakcija).
TMZ is administered orally at a dose of 75 mg/m² daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions).
TMZ se primjenjuje peroralno u dozi od 75 mg/m2 na dan tijekom 42 dana uz istodobnu radioterapiju (60 Gy primijenjenih u 30 frakcija).
TMZ is spontaneously hydrolysed at physiologic pH primarily to the active species, 3-methyl- (triazen-1-yl)imidazole-4-carboxamide (MTIC).
TMZ se spontano hidrolizira pri fiziološkom pH prvenstveno u aktivni spoj 3-metil-(triazen- 1-il)imidazol-4-karboksamid (MTIC).
TMZ is spontaneously hydrolysed at physiologic pH primarily to the active species, 3-methyl-(triazen- 1-yl)imidazole-4-carboxamide (MTIC).
TMZ se spontano hidrolizira pri fiziološkom pH prvenstveno u aktivni spoj 3-metil-(triazen- 1-il)imidazol-4-karboksamid (MTIC).
TMZ is spontaneously hydrolyzed at physiologic pH primarily to the active species,
TMZ se spontano hidrolizira pri fiziološkom pH prvenstveno u aktivni spoj
TMZ is spontaneously hydrolyzed at physiologic pH primarily to the active species,
TMZ spontano se hidrolizira pri fiziološkom pH prvenstveno u aktivni spoj
TMZ is spontaneously hydrolyzed at physiologic pH primarily to the active species, 3-methyl- (triazen-1-yl)imidazole-4-carboxamide (MTIC).
TMZ se spontano hidrolizira pri fiziološkom pH prvenstveno u aktivni spoj 3-metil-(triazen- 1-il)imidazol-4-karboksamid (MTIC).
TMZ is spontaneously hydrolyzed at physiologic pH primarily to the active species, 3-methyl-(triazen- 1- yl)imidazole-4-carboxamide (MTIC).
TMZ se spontano hidrolizira pri fiziološkom pH prvenstveno u aktivni spoj 3-metil-(triazen- 1-il)imidazol-4-karboksamid (MTIC).
TMZ is spontaneously hydrolyzed at physiologic pH primarily to the active species, 3-methyl-(triazen- 1-yl)imidazole-4-carboxamide (MTIC).
TMZ se spontano hidrolizira pri fiziološkom pH prvenstveno u aktivni spoj 3-metil-(triazen- 1-il)imidazol-4-karboksamid (MTIC).
TMZ is spontaneously hydrolyzed at physiologic pH primarily to the active species, 3-methyl-(triazen-1- yl)imidazole-4-carboxamide (MTIC).
TMZ se spontano hidrolizira pri fiziološkom pH prvenstveno u aktivni spoj 3-metil-(triazen- 1-il)imidazol-4-karboksamid (MTIC).
TMZ should not be administered to pregnant women.
Temozolomid Accord se ne smije davati trudnicama.
TMZ was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22%) in the TMZ + RT arm.
TMZ se primjenjivao kao "spasonosni" pokušaj liječenja tijekom razdoblja praćenja u 161 od 282 bolesnika (57%) u skupini u kojoj se primijenila samo RT te u 62 od 277 bolesnika (22%) u skupini koja je uz RT primala i TMZ.
TN = Treatment-Naïve
PN = prethodno nisu bili liječeni
TN and TE, without cirrhosis or with compensated cirrhosis
TN i TE, bez ciroze ili s kompenziranom cirozom
TN with or without cirrhosis
PN, s cirozom ili bez nje
TN with or without cirrhosis Opiate agonist therapy
PN, s cirozom ili bez nje Liječenje opijatnim agonistima
TNCT (median)
TNCT (medijan)